While initial response rates are similar between the Avutometinib/Defactinib doublet and single-agent Trametinib, the doublet provides double the progression-free survival (PFS). Its remarkable duration of response (over 30 months) indicates superior long-term disease control.

Hedgehog inhibitors for basal cell carcinoma cause significant side effects like dysgeusia and muscle cramps. To improve tolerability and long-term adherence, clinicians use practical strategies like scheduled treatment interruptions (e.g., weeks on, weeks off) rather than continuous daily dosing.

For ovarian cancer patients experiencing significant ocular side effects from the ADC mervituximab, switching the dosing schedule from every three weeks to every four weeks can resolve the toxicity by allowing an extra week for recovery.

To manage Dasatinib's common side effect of pleural effusions, a randomized study showed that skipping doses on weekends is superior to dose reduction. This strategy leverages the drug's short half-life, maintaining peak levels for efficacy while providing a break from off-target effects that cause toxicity.

TAMP is delivered once every two weeks, but crucially, patients generally do not receive other treatments concurrently. This regimen provides significant breaks from therapy, helping to preserve pre-procedural quality of life—a major advantage over the continuous burden of systemic chemotherapy.

To improve long-term tolerability of amivantamab, some experts advocate for a "marathon, not a sprint" approach. This involves aggressive dose holds or reductions at the earliest signs of toxicity, even low-grade, to prevent side effects from escalating and ensure patients can remain on effective therapy longer.

Data on Enfortumab Vedotin suggests that for modern therapies, maintaining patients on treatment longer via a lower, more tolerable starting dose is more important than administering the maximum labeled dose upfront, a concept inherited from the cytotoxic chemotherapy era.

A trial investigating intermittent versus continuous axitinib in metastatic RCC addresses a major clinical challenge: the significant toxicity and impaired quality of life from continuous TKI therapy. Proving non-inferiority for an intermittent schedule could fundamentally change patient management and improve long-term tolerability.

While the avutometanib/defactinib combination is newly approved for KRAS-mutated ovarian cancer, its significant toxicity profile—causing up to a third of patients to stop treatment—creates a clear clinical need for agents like specific KRAS inhibitors that may offer similar efficacy with better tolerability.